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Abstract 
The degree to which a person recognizes their mental disorder, attributes symptoms to 
the disorder, and recognizes that treatment may be necessary, is frequently referred to as 
clinical insight. The current study investigates whether clinical insight at baseline moderates 
the effects on metacognitive capacity of 40 sessions of Metacognitive Reflection and Insight 
Therapy (MERIT) among 35 participants with psychosis.  
Findings showed that clinical insight did not predict drop-out from therapy. Multilevel 
analyses provided support for our hypotheses that insight at baseline significantly moderates 
metacognitive gains at both post-measurement and follow-up. Our findings demonstrate that 
lacking clinical insight substantially hampers the effect of this psychosocial intervention. We 
posit that research efforts should shift from developing interventions which enhance clinical 
insight, to interventions which are effective in absence of clinical insight.  
Key Practitioner Message 
 Clinical insight moderates the effects of 40 sessions of metacognitive psychotherapy 
 Insight was not related to  drop-out from therapy 
 Future work should be focused on developing interventions which require no clinical 
insight 
Keywords: insight, psychotherapy, metacognition, MERIT, psychosocial intervention 
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Introduction 
It is a widely observed phenomenon within psychotic disorders that many clients do not 
share the same views as clinicians surrounding the presence or severity of their disorder 
(Amador, Strauss, Yale, & Gorman, 1991; David, 1990; Lysaker, Buck, Salvatore, Popolo, & 
Dimaggio, 2009). This awareness of disorder, along with the ability to attribute 
symptomatology to the disorder and recognizing the need for treatment, is commonly referred 
to as insight into the illness or clinical insight (David, 1990; David, Bedford, Wiffen, & Gilleen, 
2014).  
During the last decade a debate has taken place with regard to the importance of clinical 
insight, in what has become known as the “insight paradox” (Lysaker, Pattison, Leonhardt, 
Phelps, & Vohs, 2018; Lysaker, Roe, & Yanos, 2007). This paradox is in reference to some 
studies showing associations of clinical insight with positive outcomes such as treatment 
compliance, functioning and reduced relapse (e.g. Bergé et al., 2016; Gumley et al., 2014), 
while other studies showed its association with negative outcomes such as reduced quality of 
life, reduced hope, higher self-stigma and higher rates of depression and suicidal intent 
(Crumlish et al., 2005; Ehrlich-Ben Or et al., 2013; Hasson-Ohayon, Kravetz, Meir, & 
Rozencwaig, 2009; Hasson-Ohayon, Kravetz, Roe, David, & Weiser, 2006). In fact, a recent 
study showed a considerable overlap between insight and self-stigma (Hasson-Ohayon, 
2018).  
Concerning adherence to medication, studies frequently find a link between insight and 
medication non-adherence (Lacro et al., 2002; Lincoln, Lüllmann, & Rief, 2007). Lincoln et 
al., (2007) note, however, that the correlational nature of studies precludes conclusions 
surrounding directionality: it may be that medication non-adherence predicts lower insight, 
which may explain studies which find the influence of insight on non-adherence fading over 
time (Lincoln et al., 2007; McEvoy et al., 1989; Yen et al., 2005). This hypothesis is 
strengthened by a meta-analysis which has found that antipsychotic drugs have a beneficial 
effect on insight, which generally takes place in the first three months after starting medication 
(Pijnenborg et al., 2015). 
In the field of psychotherapy with persons with psychosis, insight has been repeatedly 
shown as beneficial to the therapeutic alliance (Kvrgic et al., 2013; Wittorf et al., 2009). 
Surrounding adherence, however, there are some mixed findings: some authors report insight 
as a fairly strong predictor for non-adherence to CBT in a sample of first-episode patients 
  
This article is protected by copyright. All rights reserved. 
(Álvarez-jiménez et al., 2009), while others found it does not play a significant role in service 
disengagement (refusing contact with the treatment facility; e.g. Schimmelmann et al., 2006). 
Recently, a claim has been made that clinical insight might reflect an attitude toward the 
illness and compliance with the medical model rather than a pure awareness of having a serious 
psychiatric illness (Hasson-Ohayon, 2018; Lincoln et al., 2007; Lysaker et al., 2018). 
Particularly in the case of psychosis, the medical model which might be stigmatic for some 
patients, may not apply to all. Recent evidence suggests, for instance, that around 28% of 
patients report non-adherence to medication as a result of gain from illness such as 
companionship from voices (Moritz, Favrod, et al., 2013). Illustrating that the influence of 
clinical insight on the therapeutic alliance may be similarly more complex than merely “better 
insight means a better therapeutic alliance”, this study found that 31% of respondents indicate 
they did not take their medication because of mistrust towards their physician / therapist.  
One avenue through which to approach a more reflective conceptualization of clinical 
insight may be the metacognitive framework. A recent conceptualization of metacognition 
considers it to be a person’s ability to form complex representations of oneself, others and the 
world (Lysaker & Dimaggio, 2014). Thus, it refers to reflective processes that go beyond 
viewing the self as having or not having an illness; i.e. having clinical insight and having high 
metacognition are not the same phenomenon. One study has found metacognitive abilities as a 
moderator affecting the implications of insight, i.e. for persons with higher metacognition, 
insight has more positive outcomes than for persons with low metacognition (Lysaker et al., 
2013). 
The positive implication of enhanced metacognitive abilities among persons with 
schizophrenia are extensively documented (see meta-analysis of Arnon-Ribenfeld et al., 2017), 
and lead to the development of interventions that promote metacognition (Hamm, Hasson-
Ohayon, Kukla, & Lysaker, 2013). In addition, the positive implications of metacognition 
combined with high insight was shown in a cross-sectional study (Lysaker et al, 2013) but not 
yet in therapy. Taking these findings together and further studying the interaction between 
insight and metacognition, it is speculated that a psychotherapeutic metacognitive approach 
may be warranted for one to benefit from insight. One such intervention is Metacognitive 
Reflection and Insight Therapy (MERIT; Lysaker and Klion, 2017; see materials). This 
intervention is an individual psychotherapy with a focus on joint reflection on narrative 
episodes produced by the client. As the client discusses his or her life, the therapist is constantly 
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monitoring for metacognitive activities on four domains (see Methods) and stimulating activity 
at that level, or slightly above. Particularly relevant to the current study, the intervention is 
explicitly directed toward the patient’s narrative, including the illness narrative, for joint 
reflection rather than correction. In other words: the intervention target is metacognition, rather 
than symptoms or insight. This focus is where MERIT is different from other metacognitive 
approaches (Moritz & Lysaker, 2018), which are more based on a Cognitive-Behavioral 
approach intended to increase awareness and correction of one’s own cognitive biases (Moritz, 
Veckenstedt, et al., 2013) or interpretation of symptomatology (Wells, 2009).  
Based on existing case studies, open trials and a pilot study (e.g. Bargenquast et al., 2015; 
de Jong et al., 2016a, 2016b; Dubreucq et al., 2016; Hamm and Firmin, 2016; Hillis et al., 
2015; van Donkersgoed et al., 2016), we have investigated the effects of MERIT in a 
multicenter, randomized controlled trial (de Jong, van Donkersgoed, et al., 2018). Results of 
the trial showed that both the treatment condition as well as the control condition (treatment as 
usual) improved with regard to metacognition, leading to no significant differences between 
the groups immediately post-treatment. At 6-month follow-up, however, patients in the 
treatment condition demonstrated having continued the path of metacognitive improvement, 
while the control condition lost most of the gains, leading to significant differences between 
the groups at follow-up.  
 Based on extensive clinical experience with the method by the first author of the 
therapy manual (e.g. Lysaker & Buck, 2006; Lysaker, Buck, & Ringer, 2007), a minimum of 
40 sessions was established as the minimum to allow for meaningful metacognitive gains. 
Given the length of therapy, we sought to investigate potential moderators, i.e. to identify 
factors which could predict whether patients would benefit from the treatment or not. 
In the initial analysis of the data from the randomized controlled trial (de Jong, van 
Donkersgoed, et al., 2018; de Jong, Hasson‐Ohayon, Donkersgoed, Aleman, & Pijnenborg, 
2018), it became clear that insight had not significantly improved, neither at post-treatment nor 
6-month follow-up, suggesting that the therapy did not affect insight. This finding, combined 
with the known relationship between insight and clinical outcome variables such as medication 
adherence (Hui et al., 2015), and theoretical and empirical accounts of low clinical insight as 
an obstacle to the therapeutic alliance (Hasson-Ohayon, Kravetz, & Lysaker, 2017; Kvrgic et 
al., 2013; Wittorf et al., 2009), we hypothesized that clinical insight at baseline might serve as 
a moderator of therapy effect. If confirmed, this would have significant clinical implications, 
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as it would suggest that patients with low insight will not benefit from a relatively long 
metacognitive psychotherapy and addressing the need of persons with low insight will require 
further research.  
Methods 
Participants 
All thirteen participating therapists had completed a master’s programme (MSc) of 
psychology at the university level. Most (11) therapists had completed an additional 2-year 
post-master clinical degree programme (mental healthcare psychologist). Two therapists had 
completed an additional 4-year post-master programme (Clinical Psychologist). These 11 
therapists all had several years of professional experiences with persons with a psychotic 
disorder, and are as such best considered as senior therapists. Both of the two remaining 
therapists were PhD candidates in Clinical Psychology, of which one was enrolled in the 
mental healthcare psychology post-master education.   As such, these two are best considered 
more junior or trainee therapists.  
 The full sample (n=70) is comprised of 49 men and 21 women, with a MINI-PLUS 
verified diagnosis of schizophrenia (n=47) or schizoaffective disorder (n=23), between 22 and 
67 years old, with a mean age of 40. All were in a post-acute phase of illness, with no changes 
to medication in the past 30 days and an average score of 4 or less on the Positive And Negative 
Syndrome Scale (PANSS) scale of positive symptomatology. To be considered for inclusion 
in the trial, participants had to be older than 18 years old, demonstrate impaired metacognitive 
functioning, be able to give informed consent, and must not suffer from comorbid neurological 
damage, severe substance dependence or impaired intellectual functioning (IQ<70). Further 
details of the sample are presented in table 1. 
 For the MERIT condition, participants (N = 35) were considered drop-out if they did 
not complete all 40 sessions. Five participants dropped out of the study before or during the 
first session of therapy1, however, and as such, their data was added to the Treatment as Usual 
condition. Consequently, participants were divided between the groups unevenly: MERIT (30), 
TAU (40).  We verified this did not have a meaningful impact on our outcomes by repeating 
all analyses with the original group assignment intact.  
                                                          
1 One participant came to the first session inebriated, and was sent home with the agreement of sobriety for 
the next session. Unfortunately, this client did not attend any following sessions. 
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 All participants, whether they dropped out of the study or not, were offered post-
measurements and follow-up measurements. As such, all participants had baseline scores 
entered, but for some only post-scores or follow-up scores were available. Of thirty 
remaining participants receiving MERIT, eighteen completed therapy fully. Of those twelve 
participants who dropped out, five dropped out because their therapist (n=2) could no longer 
provide the therapy. Their reasons were unrelated to the study, being maternity leave and 
leaving for international charity work. Seven participants dropped out for other reasons: too 
busy with work (n=4), too far to travel (n=2), no match with therapist (n=1), ‘doing too well’ 
according to participant (n=3).  
 Twenty-three post-measurements were completed in the MERIT condition (intention-
to-treat), of which eighteen were therapy completers. In the TAU condition, due to a clerical 
error, one baseline measurement was not entered, which combined with no-shows lead to the 
final analysis consisting of 39, 25 and 20 scores on baseline, post and follow-up respectively.   
 
Instruments 
Clinical Insight was assessed using item G12 of the Positive and Negative Syndrome Scale 
(Kay, Fiszbein, & Opler, 1987). This item is one of 30 symptoms assessed by the total scale, 
and is scored by a trained rater based on an interview which typically lasts between 30 and 45 
minutes. This item, “Lack of judgment and insight”, allows raters to assign a score of clinical 
insight based on their impression of a client’s awareness of mental disorder, attribution of 
symptoms to the disorder, and the need for treatment. Higher scores indicating lower insight 
(1 = good insight, 7 = no insight). It is a common measure of clinical insight, as it has 
demonstrated to be strongly correlated (Sanz, Constable, Lopez-Ibor, Kemp, & David, 1998) 
to more extensive measures of insight such as the Schedule to Assess Insight (Kemp & 
David, 1997) and its extended version (SAI-E), SUM-D and ITAQ.  
 Relevant to the current study, poor scores on this item have been shown predictive of 
negative attitudes towards medication adherence six months later in an adult-onset sample 
(Hui et al., 2015), while better scores were predictive of recovery from positive and negative 
symptoms 12 months later in a first-episode sample (Gumley et al., 2014). Furthermore, it has 
been shown to be sensitive to change, for instance as a result of antipsychotic medication 
(Pijnenborg et al., 2015).The scoring criteria are made available in a supplement to this 
article.  
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Metacognition was assessed using a three-step procedure. First, the participant is interviewed 
using the Indiana Psychiatric Illness Interview (Lysaker et al., 2005). This open-ended 
interview was developed to elicit the personal and illness narrative of the participant, which 
may serve as a suitable spontaneous speech sample. Audio-recordings of this interview are 
transcribed, so as to ensure that only the content of what is said is used as an estimate of 
metacognitive capacity rather than peculiarities of speech such as slurred, slow or monotonous 
speech. Ratings of metacognition are then made individually by raters, who have completed a 
4-hour training in the Metacognition Assessment Scale – A (Lysaker et al., 2005). Because 
raters were generally master’s students of psychology, the third step was to organize consensus 
meetings during which all ratings were discussed with a minimum of three raters, of which one 
was always a PhD candidate in Psychology, to come to a final score. The MAS-A has seen 
widespread use in studies of psychosis, and has demonstrated good psychometric properties 
(Hasson-Ohayon et al., 2015; Lysaker et al., 2014; Rabin et al., 2014).  
 The intervention (MERIT; Lysaker and Klion, 2017) is an integrative psychotherapy 
developed to assist persons with a psychotic disorders (re)gain metacognitive capacity. The 
MERIT protocol was translated from English, and adapted to a Dutch context by SJ and RVD 
under supervision of MP and a psychologist with a post-master degree (GZ-education) in 
clinical psychology. The protocol does not offer a session-by-session program, but rather 
emphasizes eight elements which therapists should strive to include in every session. These 
elements are I) being open to the agenda of the client, II) offering of the therapists’ thoughts 
regarding the patient’s behavior during the session, III) eliciting a personal narrative, IV) 
framing a psychological problem to be discussed, V) eliciting reflections on the interpersonal 
processes that occur during the sessions, VI) eliciting reflections on the progress of the session 
or treatment. The final elements are stimulating metacognitive self-reflectivity and reflections 
on others (VII) and metacognitive mastery (VIII) using questions and reflections tailored to the 
current metacognitive functioning of the patient. An in-depth discussion of each of these 
elements in practice can be found in several case studies (e.g. Lysaker and Buck, 2006), 
including the treatment of a person with persistent negative symptoms (de Jong, van 
Donkersgoed, Pijnenborg, et al., 2016b), severe symptoms of disorganization (de Jong, van 
Donkersgoed, Pijnenborg, et al., 2016a), and one client who reached maximum levels of 
metacognitive capacity at therapy end (Buck & George, 2016).  
 Treatment as Usual was defined as the maintenance of antipsychotic medication and 
the remainder of any short-term ongoing interventions, as well as supporting contact with 
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their healthcare teams, exactly as they had before entering the study. Participants and staff 
were instructed not to begin any new psychosocial interventions during the study period (10 
months). Two out of 35 participants indicated they had met with a psychologist in the 10 
months of the study.  
Procedures 
Thirteen therapists from seven different mental healthcare institutes in the Netherlands were 
trained in the intervention by PL, during a 3-day training. Throughout the study, all therapists 
received bi-weekly group supervision via internet telephony, offered by the first author of the 
intervention (Lysaker & Klion, 2017). Therapists were asked to complete a measure of 
adherence to the intervention after each session throughout the study, and it was verified that 
they had. These were intended, however, as a basis for supervision rather than formal scientific 
analysis, and as such were not analyzed.  
 All patients in their caseloads were screened for eligibility based on the in- and 
exclusion criteria. All eligible participants were then coarsely screened on metacognitive 
functioning by their case manager or staff member most familiar with them, using four 
questions based on the four scales of the Metacognition Assessment Scale-A (e.g. “To what 
extent is the patient able to think about his or her own thoughts”) answered on a 10-point scale, 
with higher scores indicating better functioning. All patients who scored lower than 6 on two 
or more of these questions were approached for participation by a research assistant, and 
offered an information letter. In describing the intervention, emphasis was placed on 
metacognitive capacity as a target for the intervention, with the only reference to a diagnosis 
of psychosis in the inclusion criteria.  
 A more detailed description of the inclusion procedure, as well as the full test battery, 
is available elsewhere (de Jong, van Donkersgoed, et al., 2018). Participants were tested at 
three different occasions, at baseline, immediately post therapy (after 40 sessions in the 
treatment condition, or after 10 months in the control condition) and at 6-month follow-up. 
After baseline assessment, eligible patients were randomized by an independent third party. 
During subsequent assessments, all ratings were performed by research assistants blind to 
condition.  
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Analyses 
Differences between the treatment group and control condition were tested using SPSS 
Statistics version 25, utilizing two-tailed independent-samples t-tests (age) or Fisher’s Exact 
Test (gender, diagnosis), with significance levels set at α=0.05. 
 Before progressing to the moderator analysis, a binary logistic regression analysis was 
performed, with drop-out (yes/no) as the dependent variable, and insight at baseline entered 
as the predictor, was conducted to determine if insight at baseline might be a significant 
predictor for drop-out.  
 All further analyses were conducted using multilevel analysis in the computer software 
MLWiN 3 (Charlton, Rasbash, Browne, Healy, & Cameron, 2017). Multilevel analysis is 
uniquely suitable to take into account nested data and deal with missing data (Field, 2013; 
Snijders & Bosker, 2000). In our case, three possible levels were considered: therapist, 
participant and time of assessment. From our previous analysis, it was clear that the “therapist” 
level does not significantly add to the model, and as such, only a two-level model was 
constructed: participant at level 2, and time of assessment at level 1. Because we were 
interested in whether insight at baseline is a significant moderator, insight scores at all 
measurement moments were replaced by baseline scores.  
 Separate models were constructed for each of the outcomes (MAS-Total and individual 
subscales), as the dependent variable, dummy variables representing time (T1 or T2) and 
interactions terms of T1*condition and T2*condition. The improvement of the model fit caused 
by adding the interaction terms under investigation (T1*condition*insight and 
T2*condition*insight) is tested utilizing the deviance test (Snijders & Bosker, 2000), with a 
significance level set to α=0.05. 
 All tests were conducted twice: an initial exploration on the full dataset, otherwise 
known as “intention-to-treat”. Given significant drop-out early in the therapy (sessions 
1,2,6,8,9,13,20 and 22), however, this does not represent a pure test of the intervention as it is 
intended. As such, follow-up analyses were conducted on each of the four MAS-A subscales, 
using only data of completers (i.e. who had completed 40 sessions of MERIT or completed all 
measurements in TAU). As with the intention-to-treat analysis, participants in the MERIT 
condition who had not attended any full sessions were added to the TAU group2, so their data 
                                                          
2 One participant came to the first session inebriated, and sent home with the agreement of sobriety for the 
next session. Unfortunately, this client did not attend any following sessions.  
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could be included in the analysis. This total completers-sample consisted of 58 participants 
(TAU=40, MERIT=18). For participant flow, see figure 1.  
 Finally, we explored in both intention-to-treat and sensitivity datasets whether any 
possible overlap between metacognition and clinical insight at baseline would have influenced 
our results. A bivariate correlation analysis was conducted to this effect, and separate models 
were constructed including interaction terms of insight with baseline metacognition 
(t1*condition*baseline metacognition and t2*condition*baseline metacognition) to test their 
contribution to the model.  
Results 
Demographic and background variables are presented in table 1. Our sample was, on average, 
40 years old, predominantly male (M:41, F:29), with a diagnosis of schizophrenia (Sz: 47, Sa: 
23), with an average duration of illness of 14 years. Groups did not differ significantly on these 
characteristics.  
 
Binary logistic regression analysis revealed that clinical insight was not a significant predictor 
for drop-out from the study (wald=.4(1), p= .527) or from the therapy group separately 
(wald=.028 (1), p= .868).  
 
Visual inspection of the data heavily suggested a moderating effect of insight on metacognitive 
gains. For ease of interpretation, in figures 2 and 3, we have performed a median split on 
clinical insight. The median, coincidentally, fell at a PANSS G12 (insight measure) score of 2. 
In the scoring criteria of the PANSS, 2 or less is generally considered as “not clinically 
impaired”. In all analyses, raw PANSS-G12 scores were used, rather than the median split 
represented in the figure.  
 
Multilevel analyses confirmed our hypothesis: in both intention-to-treat (Table 2) as well as 
completers-analyses (Table 3), clinical insight significantly moderated the interactions on total 
scores of metacognition, as well as the subscales of Self-Reflectivity at follow-up and 
Understanding the Other’s Mind at post and follow-up. Decentration is moderated at post and 
follow-up in intention-to-treat, but only at post in the completers-analysis (although significant 
at a trend level, p<.1). No moderating effect was found on metacognitive Mastery. Given the 
nature of drop-out being slanted towards non-therapy related (N=10) versus possibly therapy 
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related (N=7), it is impossible to conclude whether the intention-to-treat or the completers 
analyses would provide a more accurate picture of therapy and moderation effects.  
 
These findings demonstrate that for persons in the psychotherapy group, level of 
baseline insight predicts the development of metacognitive capacity significantly different 
from treatment-as-usual (i.e. no intervention). Figures 2 and 3 demonstrate this moderating 
effect: persons with high insight at baseline demonstrate improvements in metacognition in the 
therapy group, while low insight in the therapy group predicts very little to no improvement. 
Without psychotherapy (TAU), insight bears no relationship to metacognitive gains over time.  
Finally, we sought to explore whether our results could be influenced by any possible 
overlap between the constructs of clinical insight and metacognition. Baseline metacognition 
scores and baseline clinical insight scores did not correlate significantly (Pearson’s r = -.14, p 
=.25). Adding interaction effects of insights with t1*condition*baseline metacognition and 
with t2*condition*baseline metacognition) did not prove significant contributions to the 
model. To ensure our adjustment to group membership had no meaningful effect on the 
analyses, we repeated the analyses with the original assignments intact. All results remained 
identical vis-à-vis significance levels.  
 
Discussion 
The current study examined whether clinical insight may serve as a moderator on the 
effects of metacognitive psychotherapy. Our findings support our hypothesis that persons 
with higher clinical insight at baseline show more metacognitive gains than persons with 
lower clinical insight when psychotherapy is applied. Furthermore, persons with low clinical 
insight demonstrated little to no metacognitive improvements from the intervention. In the 
group of participants who received no psychotherapy whatsoever, higher or lower clinical 
insight had no implications for the development of metacognitive capacity.  
The interaction that was found between participating in psychotherapy and insight 
extends our previously reported results from the RCT indicating that persons improved on 
metacognitive self-reflectivity at follow-up, and that there was a possible effect on 
metacognitive mastery while no effects were found on Understanding the Other’s Mind or 
Decentration (de Jong, van Donkersgoed, et al., 2018). The current study findings suggest 
clinical insight moderates therapy effects on Other and Decentration, but not Self and Mastery 
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at post and follow-up. Thus, immediate effects of (metacognitive) psychotherapy are highly 
dependent on clinical insight at baseline.  
 We see, among others, two possible, related explanations for these findings. The first 
one relates to insight as a component of readiness for change and the second one relates to the 
response of the therapist to patients with low versus high insight. Considering change, if a 
person does not believe he or she has a disorder, taking an active role for change is doubtful. 
If a person lacks a coherent account of having an illness (although he or she can have a coherent 
account that does not comply with the medical model, see Roe et al., 2008), then reflecting 
together with a mental health professional on life makes very little sense to that person. While 
intuitively appealing, this interpretation may be an oversimplification. For some patients, this 
direct relationship may certainly be the case, but these patients are unlikely to ever actually 
show up for sessions at all. Our analyses did not show a relationship between low insight and 
drop-out. This may be due to low power, but it is more likely that participants who signed up 
for the rather long trial (40 sessions) were actually motivated for treatment, having low insight 
or not. Participants who were not motivated, and thus did not appear for even a single session, 
were re-classified in our analyses as “treatment-as-usual”; in a clinical setting, their therapy 
would be unlikely to ever start.  
 The second explanation takes into account the possible therapist’s contribution to the 
findings. Understanding the findings from an intersubjective framework (Hasson-Ohayon et 
al., 2017), the working alliance may be threatened from the beginning of the therapy when 
patients express low insight, causing a fundamental rift between him/her and the therapist in 
the formation of a joint goal. According to the intersubjective model, therapist and client may 
differ in their views of the client’s issues and their own roles in treatment, views that are highly 
related to insight into the illness (Hasson-Ohayon et al. 2017). It is possible that greater insight 
into illness means that patient and therapist agree on the diagnosis and need for treatment. This 
starting point may allow for productive therapeutic work to take place. This idea is supported 
by studies that showed therapists tend to rate the therapeutic alliance more positively with 
patients who display greater levels of insight (Ruchlewska, Kamperman, van der Gaag, 
Wierdsma, & Mulder, 2016) and agree more with patients with high insight than with patients 
with low insight on different aspects of the patients life (e.g. Hasson-Ohayon et al., 2011; 
Lysaker et al., 2012). In comparison, if a patient lacks insight, the therapist may feel an urge to 
provide the patient with a narrative in line with the medical model leading to unproductive 
arguments about whether the patient does or does not have an illness or symptoms. Going 
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beyond our data, we consider it a possibility worth exploring that the therapist forms higher 
agreement and better alliance with persons with higher insight than low insight. In other words, 
there may be some version of a self-fulfilling prophecy or ‘Pygmalion’ effect (Rosenthal & 
Jacobson, 1968) at work. There is some basis for this assumption; it has been found, for 
instance, that healthcare professionals are generally less optimistic about the possibility of 
recovery from mental illness than the general public (e.g. Hugo 2001). Patients lacking in 
clinical insight may cause healthcare professionals and caregivers to experience a sense of 
helplessness when confronted with, for instance, severe disorganization, negative symptoms or 
rigidly-held beliefs surrounding delusional convictions or hallucinations. This sense of 
helplessness may translate to less expectation for recovery and thus, less recovery. To 
investigate this hypothesis, we would recommend that in future studies, measures of 
hope(lessness), expectations of outcomes and therapeutic alliance are administered to both 
clients and therapists. Alternatively, future studies surrounding MERIT and insight may 
include a special section for low-insight clients, in which the therapist is guided towards 
interventions at the lowest levels of metacognitive mastery.  
Based on the intersubjective model (Hasson-Ohayon et al., 2017), as well as relatively 
recent findings that persons with psychosis report ambivalent or even positive attitudes towards 
their psychotic symptoms (Moritz et al., 2015; Moritz, Favrod, et al., 2013), some adjustments 
could be made to the protocol. For instance, an addition could be made to the protocol where, 
in absence of clinical insight, the therapists are guided in exploring the illness narrative with 
the client. Questions which may serve as fruitful ground for joint reflection may be an explicit 
discussion of the patient’s views surrounding any mental difficulties they experience, and what 
goals are for the coming few years.  This may ensure a focus, from the very first moment, on a 
shared reality from which to begin work on personal recovery rather than the contentious matter 
of symptomatic improvement when insight is absent.  
Several limitations to this study should be taken into account: the sample size is modest, 
given how participants were divided between two conditions and insight was only measured 
utilizing the single PANSS G12 item. Due to the mix of drop-out due to therapist attrition and 
patient attrition before session 0 (we hypothesize that these patients were mainly stimulated by 
the prospect of €20 compensation for each measurement moment), it is difficult to say whether 
the strong effects in the intention-to-treat analysis or the much less strong effect in the 
completers analysis is the most accurate. The accuracy of the reasons for drop-out is difficult 
to verify, as such we maintained the strictest definition of drop-out after therapy start, namely 
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discontinuation of the intervention for any reason at all. It is possible that the reason of ‘doing 
too well’ given by some participants reflects therapy success rather than therapy rejection (Roe, 
Hasson-Ohayon, & Gornemann, 2016). Conversely, however, this reason as well as all the 
others may be more socially desirable answers obfuscating drop-out because of non-
acceptance. As such, we stress that both intention-to-treat analysis and completers analysis 
warrants attention. Furthermore, with a mean years of illness of 13.5, our data may very well 
not generalize to first-episode patients. Therapeutic alliance measures could not be 
administered to clients and therapists, and as such our notions surrounding the influence of 
insight on the therapeutic alliance remain theoretical. Similarly, therapist adherence to the 
therapy manual was only ensured through post-session self-rating by the therapist and bi-
weekly supervision. As such, no formal measure of adherence could be entered into the model 
to determine whether more or less adherence to the protocol influences therapy effects. Finally, 
our findings may not be generalized to other forms of psychotherapy such as cognitive-
behavioral therapy.  
Our findings demonstrate that psychotherapy such as MERIT may be significantly 
hampered by lacking clinical insight to the degree that it may be fruitful to open the discussion 
on whether such psychosocial interventions should be undertaken in the absence of clinical 
insight. We propose that efforts should be shifted, moving from interventions intending to treat 
(or ‘enhance’) clinical insight towards interventions which can be applied in the absence of 
clinical insight. One possibly fruitful avenue in this may be the development of training 
modules specifically designed for professionals who work with persons with a psychotic 
disorder, and which offer hands-on suggestions on how to deal with lacking insight or low 
metacognitive mastery.  
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Table 1 
Comparison of demographic variables between the groups 
Variable Control (n=40) MERIT (n=30) p T-test / χ2 
Age in years (SD) 38.18 (10.74) 42.47 (12.05) 0.121 
Gender    
     Male 30 11 0.307 
     Female 10 19  
Diagnosis    
     Schizophrenia 26 21 0.798 
     Schizoaffective 14 9  
Yrs of illness, mean (SD) 12.08 (9.15) 16.10 (12.15) 0.16 
 
 
Table 2 
Fixed and random effects on the moderation of insight on outcomes between the groups  – intention to treat 
 Self Other Decentr. Mastery  MAS-
Total 
Parameter  Beta (SE) Beta (SE) Beta (SE) Beta (SE) Beta (SE) 
Fixed effects      
Time factor      
  Baseline 4.15(0.14) 2.60(0.09) 1.04(0.06) 3.14(0.15) 10.93 (0.35) 
  Post time-effecta 0.24(0.23) 0.03(0.16) 0.07(0.11) 0.89(0.24) 1.26(0.55) 
  Post*Conditiona 1.05(0.58) 0.95(0.40) 0.69(0.27) 0.50(0.62) 3.04(1.42) 
  Follow-up time-effectb -0.01(0.24) -0.04(0.17) 0.17(0.11) 0.84(0.26) 0.10(0.59) 
  Follow-up*Conditionb 2.63(0.84) 1.58(0.58) 0.78(0.39) 1.70(0.89) 6.43(2.05) 
  Insight * Condition * Post -0.3(0.18) -0.24(0.12)† -0.22(0.08)** -0.26(0.19) -0.99(0.44)* 
  Insight * Condition * FU 
-0.52(0.26)* -0.44(0.18)* -0.29(0.12)* -0.48(0.28)† 
-
1.67(0.63)** 
      
Random effects 
Variances of 
     
      Level 2 – intercept 0.43(0.15) 0.18(0.07) 0.09(0.03) 0.73(0.21) 3.55(1.06) 
      Level 1 – residual 0.87(0.13) 0.43(0.07) 0.19(0.03) 0.94(0.14) 5.00(0.75) 
aPost effect: Difference between T0 and T1 (TAU is reference category) 
bFollow–up effect: Difference between T0 and T2 (TAU is reference category) 
 
** = significant at p<.01, one-tailed 
* = significant at p<.05, one-tailed 
† = trend (p<.1) 
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Table 3 
Fixed and random effects on the moderation of insight on outcomes between the groups  – completers analysis 
 Self Other Decentr. Mastery  MAS-Total 
Parameter  Beta (SE) Beta (SE) Beta (SE) Beta (SE) Beta (SE) 
Fixed effects      
Time factor      
  Baseline 4.07(0.15) 2.57(0.11) 1.02(0.07) 3.20(0.15) 10.85(0.37) 
  Post time-effecta 0.29(0.23) 0.05(0.17) 0.08(0.10) 0.86(0.23) 1.30(0.54) 
  Post*Conditiona 1.58(0.61) 1.19(0.44) 0.95(0.28) 0.77(0.61) 4.24(1.49) 
  Follow-up time-effectb 0.03(0.24) -0.01(0.18) 0.18(0.11) 0.81(0.24) 1.04(0.58) 
  Follow-up*Conditionb 2.96(0.84) 1.63(0.61) 0.73(0.39) 1.74(0.84) 6.75(2.03) 
  Insight * Condition * Post -0.38(0.19)† -0.32(0.14)* -0.27(0.09)** -0.27(0.20) -1.17(0.47)* 
  Insight * Condition * FU -0.56(0.26)* -0.41(0.19)* -0.23(0.12)† -0.32(0.27) -1.44(0.64)* 
      
Random effects 
Variances of 
     
      Level 2 – intercept 0.37(0.15) 0.20(0.08) 0.11(0.04) 0.55(0.18) 3.26(1.05) 
      Level 1 – residual 0.86(0.14) 0.46(0.07) 0.17(0.03) 0.81(0.13) 4.76(0.75) 
aPost effect: Difference between T0 and T1 (TAU is reference category) 
bFollow–up effect: Difference between T0 and T2 (TAU is reference category) 
 
** = significant at p<.01, one-tailed 
* = significant at p<.05, one-tailed 
† = trend (p<.1) 
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